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A bstract
The lentivirus Equine Infectious Anemia Virus (EIAV) cau ses
an acute infection in horses which is characterized by fever,
viremia, thrombocytopenia, edem a, and hemolytic anemia.

Most

horses survive the acute disease, but remain persistently infected
for life.

The exact mechanism whereby horses' control their

initial infection is unknown, though it appears likely that cellular
immune mechanisms are involved.

T lymphocytes have been shown

to play a major role in the recovery from a variety of viral
infections, though their role in EIAV infection has not been
established.

We tested peripheral blood mononuclear cells (PBMC)

from ElAV-infected ponies for evidence of a cell-mediated
immune response to this virus.

PBMC from infected ponies

exhibited ElAV-specific lymphoproliferation upon in vitro
stimulation with viral antigen.

Cytolytic effector cell activity of

th ese celts w as determ ined by lectin-mediated cytotoxicity
assay s and by the production of serine esterase.

To investigate

the role of cell-mediated immune responses in protection from
ElAV-induced disease, the T cell responses to EIAV in vaccinated
ponies were analyzed.

Ponies were vaccinated with an inactivated

EIAV whole virus vaccine or a subunit vaccine enriched in EIAV
envelope glycoproteins.

The in vitro

lymphoproliferative

response was shown to be mediated by T lymphocytes and was
indistinguishable from that induced by EIAV infection.

Although

both vaccines stim ulated ElAV-specific cell-m ediated immunity,

x

upon in vivo challenge with virulent or avirulent EIAV it was
determ ined that the whole virus vaccine conferred protection
while the subunit vaccine appeared to exacerbate disease.

EIAV

specific cell-m ediated immunity w as also dem onstrated by
antigen specific proliferation of T cells from infected and
vaccinated ponies in response to viral proteins and peptides.

By

identifying the segm ents of gp90 and gp45 that were reactive in
th ese cell-mediated immune response assay s, this study will aid
in the development of possible vaccines against EIAV and other
related retroviruses including HIV-1.

xi

Chapter I
I n tr o d u c t io n
Purpose of the Study
Lentiviruses ca u se persistent infections characterized by
unchecked virus replication in the presence of virus specific
antibodies (Adams and Bell, 1976).

In contrast to other

lentiviruses models, the horse is capable of limiting virus
replication during persistent equine infectious anem ia virus
(EIAV) infection.

This restriction of virus replication ap p ears to

be immune-mediated and probably involves cell mediated immune
responses (Kono, et at., 1976, Perryman, et at., 1988). Thus the
horse provides a unique model for identifying protective cellmediated immune responses to lentivirus following infection and
vaccination.
Equine infectious anem ia virus is unique among lentiviruses
because most horses, although infected for life, are able to
immunologically control the disease.

Determining the a re a of the

immune response responsible for this protection and what viral
protein(s) elicit this response are of critical importance.

One of

the difficulties in vaccine design with other lentiviruses is the
natural infection does not lead to protective immunity.

In

contrast, an EIAV vaccine that induces a similar immune response
a s natural infection could protect naive horses from EIAV disease.

1

2
Due to these unique features, EIAV is an important animal model
in lentivirus research.
The purpose of this research project w as to characterize the
virus specific cell-mediated immue responses generated in ponies
sensitive to EIAV either by infection or vaccination.

Synthetic

peptides w ere used to identify immunologically important
segm ents of EIAV glycoproteins. The immune response to gag
proteins w as also studied.
The overall goal of this research project w as to identify,
m easure, and characterize cell-mediated immune (CMI) responses
of ponies infected with EIAV. The value of this research will be in
characterizing the immune responses that could m ediate control
of the recurrent viremia and associated clinical episodes.

This

study provides new insight in the role of humoral and cellm ediated immunity in this persistent infection.

By identifying the

segm ents of gp90 and gp45 that are reactive in the CMI assay s and
by demonstrating that a synthetic vaccine against EIAV could
confer som e protection, this study will aid in the developm ent of
possible vaccines against EIAV and other related retroviruses
including HIV-1.

3
Literature Review

The equine infectious anaem ia virus (EIAV) is a member of
the family Retroviridae (Issel, et at., 1979; McGuire, et at., 1979).
This family of single-stranded RNA viruses includes the three
subfamilies, oncovirinae, spumavirinae, and lentivirinae.

All

three subfamilies of retroviruses use reverse transcription and
the viral enzyme reverse transcriptase to copy the single strand
RNA viral gem one into a double strand DNA intermediate which
persist in the infected cell either integrated into the host cell
chromosom e or in the episomal form (Jarrett, 1987; Levy, 1986).
The retroviruses may enter the host cell by an exogenous route in
which the virus attaches to specific receptors on the cell surface
and enters through the cell membrane, or by an endogenous route
in which the virus enters the germ line of the host (Levy, 1986).
Another feature of this family of viruses is that they m ature by
budding from the plasm a membrane of host cell (Issel, et at.,
1979; McGuire, et at., 1979).

The genomic organization of all

retroviruses is similar, encom passing three major genes, the
group specific antigen (gag), polymerase (pol), and envelope (env).
EIAV is a member of the subfamily lentivirinae (slow
viruses), a group of non-transforming exogenous viruses, which
also includes Maedi-Visna Virus (MW) of sheep, Caprine Arthritis
Encephalitis Virus (CAEV), Simian (SIV), Bovine (BIV), Feline (FIV)
and Human (HIV) immunodeficiency viruses (Pedersen, et at., 1987,
Jarrett, 1987; Haase, I986; Levy, 1986).

The lentiviruses are
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unique in their generation of envelope antigenic variants (Haase,
1986; Levy, 1986).

Characteristics of the d ise a se s associated

with these viruses include long incubation periods and the
establishm ent of persistent infections (H aase, 1986).

This

retroviral persistence in the host is partially due to the
incorporation of viral g en es into the host chromosomal DNA,
thereby avoiding the host immune surveillance system (Jarrett,
1987), and partially due to the generation of envelope antigenic
variants (H aase, 1986).

Lentiviruses have the basic retroviral

genom e which includes flanking long terminal repeats (LTR) with
promotor and enhancer regions, but the lentiviruses have the
additional domains, the NRE and the transactivation response
region (TAR) (Haase, 1986; Rushlow, et at., 1986). The TAR region
responds to the trans-activating protein (TAT) protein which
trans activates viral g en es and increases viral replication
(Sherman, et at., 1988; Rushlow, et at., 1986).

The genomic

structure of the retroviruses is com posed of regions coding for
the gag, pol, and env proteins (Levy, 1986).

The lentivirus

subfamily of retroviruses contains overlapping gag and pol genes
in different reading frames and a non-overlapping env gene
(Rushlow, et at., 1986).
The El A virus has a single stranded RNA genom e of about 9
kilobases and the core nucleoid is enclosed in an lipid containing
envelope with glycoprotein spikes.
about 100nm in diameter.

The virus is spherical and

The virus life cycle involves

attachm ent and entry by receptor mediated endocytosis, reverse
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transcription of the viral genome, integration of the DNA into the
host genom e, transcription of the viral proteins with host RNA
polymerase, translation of the mRNA by the host ribosomes, virion
assem bly, and release by budding through the plasma membrane.
The genom e structure of EIAV includes 6 open reading frames
(ORF) organized in the following manner, 5' LTR gag pol S1 S2 env
S3 LTR 3'. The LTR like other lentiviruses is com posed of U5, R
and U3. Unique sequence 5' (U5) is 36 base pairs long and contains
the primer binding site for tRNA initiation of minus strand
synthesis (Derse, et a/., 1987). The repeat sequence (R) is 77 base
pairs long and contains the TAR sequence. Unique sequence 3* is
189 base pairs long and includes promotors.
has been identified as the EIAV TAT.

The S1 gene product

This protein shares

structural and functional homology with the HIV-1 TAT protein
(Stephens, eta!., 1990). The S3 gene is believed to encode the
EIAV Rev (regulator of expression of virion proteins) protein
(Stephens, et at.,1990).

The S2 protein is expressed in infected

animals, but the function remains unknown (Schiltz, et at., 1992).
The gag gene codes for the structural proteins of the viral core
including p15, p26, p11, and p9.
nonglycosylated.

These internal core proteins are

The p15 phosphoprotein forms a continuous inner

coat of the envelope.

The structural protein p26 is the primary

component of the core shell and is the antigen used in the
commercial agar gel immunodiffusion (AGID) test (Issel, et at.,
1966). The internal proteins also include the acidic protein p9 and
the basic protein p11.

The pol gene codes for the viral enzymes
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needed for replication, including the reverse transcriptase.

The

predominant antibody response during EIAV persistent infections
is directed against the two viral envelope glycoproteins, the
external hydrophilic, highly glycosylated gp 90, and the
transm em brane hydrophobic, slightly glycosylated

gp 45

(Montelaro, et at., 1984; Issel, et at., 1986; Rushlow, et at., 1966;
Hussain, et at., 1987).
Equine infectious anem ia or swamp fever is a chronic
relapsing infectious d isease of horses that persist for life
(Cheevers, et at., 1985; Issel, et at., 1979).

This equine disease is

found worldwide, and in the United States the highest number of
c a s e s are from the gulf coast region (Issel, et at., 1986).

The

clinical characteristics of this d isease are cycles of fever, acute
hemolytic anemia, depression, edem a, anorexia, leukopenia, and
thrombocytopenia (Issel, et at,, 1984).

The anem ia results from

both suppression of erythropoiesis and destruction of
erythrocytes that are coated with a viral hemagglutin, the
antivirus antibody and complement (McGuire, et at., 1990; Issel, et
at., 1986).

EIAV and antibody can form circulating immune

com plexes which elicit fever and cau se glomerulonephritis when
they are deposited in the kidney (Cheevers, et at., 1985; Shively,
e ta /., 1982; McGuire, et at., 1979).

The thrombocytopenia

associated with EIA appears to be mediated by the clearance of
platelets with immune com plexes on their surface (Clabough, e t
at., 1991).

The thrombocytopenia in HIV infections is believed to

be immune mediated, however the exact m echanism s involved have
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not been determined (Riqaud, et al., 1992).

Although the immune

response to EIAV results in clinical disease, immune suppression
with increased susceptibility to opportunistic infections do es not
occur in EIA.

The primary target cell in which the virus replicates

is the macrophage (McGuire, et a l, 1986). The virus is transmitted
by the interrupted feeding of insects, primarily the horsefly and
by the use of contaminated needles (Issel, et al., 1988).

The life

time persistence of this virus in the infected horse is attributed
to the antigenic variation of the envelope glycoprotein (Payne, et
al., 1987; Salinovich, e t al., 1986) and to the integration of the
viral genom e into the host genom e resulting in latently infected
cell which are not recognized by the immune system of the host
(Derse, et al., 1987).

The antigenic variation explains the

recurrent nature of EIA and the failure of classical vaccines
(McGurie, et al., 1979).

Most horses infected with EIAV eventually

control the d isease, though they remain persistently infected.

The

AGID test which accurately dem onstrates the presence of
antibodies to EIAV, is used to identify infected horses. (Issel, et
al., 1979).
One of the critical questions to answ er in lentiviral
research is which type of immune response is responsible for
protection against d isease and/or infection (Berzofsky, et al.,
1991).

The adaptive immune responses are generally divided into

humoral and cellular components.
antibody production.

The humoral response refers to

B ceils are responsible for producing

antibody which inactivates celt free virus, that is it neutralizes
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viral infectivity.

In addition to neutralizing virus, the antibody

produced by S cells in combination with complement can lyse
virus and virus infected cells.

Antibody labeled cells can also be

lysed by various cytolytic effector cell including natural killer
cells and macrophages.

The m acrophages also function as antigen

presenting cells and play a central role in the induction of the
cellular immune response.

While virus specific antibodies may be

effective in limiting initial viral infections, cell-m ediated
immunity is essential for clearance of the infection.

Indeed,

successful immune response to viral infections is T cell
dependent, since the antibody response requires T cell help,
important antiviral cytokines are produced by T cells, and
cytotoxic T cells are crucial for eliminating intracellular
infections.

The central role of the T cell has been dem onstrated in

various viral infections (Larsen, et a/., 1984; Mitchell, et et.,
1985), and th ese cells probably play a similar role in lentivirus
infections.

To a s s e s s the role of CMI in disease, a convenient

assay for measuring this response is needed.

An in vitro assay

that is considered to correlate with cell m ediated immunity in
vivo

is the antigen specific proliferation of lymphocytes.

The

presentation of antigen to T lymphocytes induces cellular
proliferation that results in the selective expansion of antigen
specific clones of T cells.

Numerous studies dem onstrated that

peripheral blood mononuclear cells (PBMC) from HIV infected
individuals proliferate in response to in vitro

stimulation with

purified live HIV, inactivated HIV, purified envelope glycoprotein,
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viral antigens and envelope peptides (Berzofsky, et al., 1991;
Krowka, et al., 1990; Schrier, et al., 1989; Eichberg, et al., 1987;
Zarling, et al., 1986).

Immunization with vaccinia virus

expressing HIV glycoproteins (Picard, et al., 1992; Zarling, et al.,
1986), HIV envelope glycoprotein vaccine (Keefer, et al., 1991;
M annhalter, et al., 1991) and with glycoprotein synthetic peptides
(Hart, et al., 1991; Berzofsky, et al., 1991; Vahlne, et al., 1991)
primed recipients for the
response.

in vitro

antigen-specific proliferative

Besides measuring lymphocyte proliferation,

quantitative assay s have been developed to m easure the killing of
antigen labeled target cells by specific cytotoxic T lymphocytes
which are an important part of cell-m ediated immunity.
Circulating HIV-specific cytotoxic lymphocytes exist in
asymptomatic seropositive HIV patients and th ese cells d ec rease
a s the patients clinical status deteriorates (Autran, et al., 1991;
Hoffenback, et al., 1989).

The existence of HIV specific cytotoxic

lymphocytes in HIV seropositive subjects has been reported using
target cells labeled with env (gp160) and gag (p55) precursor
proteins (Riviere, et al., 1989), gag p24 protein ( Koup, et al.,
1991), NEF (Culmann, et al., 1991) and VIF (Riviere, et al., 1989)
regulatory proteins, and with envelope gp 120 synthetic peptides
(Dadaglio, et al., 1991).

Antibody-dependent cell-mediated

cytotoxicity (ADCC) to HIV envelope glycoprotein external and
transm em brane portion has been described (Tyler, et al., 1989;
Blumberg, et al., 1987).

This cytotoxic reaction is mediated by Fc

receptor bearing kilter cells that recognize target cells with
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specific antibody bound to their surface.

This cytotoxic reaction

do es not involve cytotoxic T lymphocytes and its role in vivo is
unknown, although it has been suggested that it may be an early
host response in HIV infections (Tyler, et a/., 1989).
Ju st a s with HIV, the protective immune response and the
viral proteins involved are not known for other lentiviruses.

In

simian immunodeficiency virus (SIV), there is no correlation
between levels of neutralizing antibody or levels of ADCC and
protection of vaccinated animals (Hartung, et a/., 1992; MurpheyCorb, eta!., 1989). Since the antibody response alone is probably
not protective, characterizing the T cell mediated immunity is
important with this and all lentiviruses.

A specific cytotoxic T

lymphocyte response was dem onstrated in animals vaccinated
with vaccinia SIVmac (Shen, et al., 1991).
Another lentivirus recently described is the feline
immunodeficiency virus (FIV), which cau ses an "AIDS” like
syndrome in cats (Pedersen, et a l, 1987).

Very little has been

reported on FIV or the cell-mediated immune response to this
virus.

There is evidence to suggest that T cell dysfunction is an

important part of the clinical disease, since lymphocytes from FIV
infected cats had lower mitogen response that uninfected cats
(Lin, et a l, 1990).
Equine infectious anem ia virus is unique among lentiviruses
in that most horses, although infected for life, are able to
immunologically control the disease.

Identifying both the immune

response responsible for this protection and the viral protein(s)
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which elicit this response is of critical importance for the
development of a successful vaccine.

One of the difficulties in

vaccine design for other lentiviruses is that natural infection
does not lead to protective immunity.

In EIAV, however, a vaccine

that induces a similar immune response a s natural infection could
protect naive horses from EIAV disease.

Due to these unique

features, EIAV is an important animal model in lentivirus
research.

As with other viruses, there is evidence that cell-

mediated immunity plays an important role in EIA control.

Horses

that are asymptomatic carriers have episodes of viremia and
clinical d isease when treated with im m uonosuppressive drugs,
suggesting CMI involvement (Kono, et al., 1976).

Additional

support that immune response controls EIAV d isease is found in
foals lacking functional T and B cells due to combined
immunodeficiency (CID). These CID foals fail to terminate the
viremia cau sed by EIAV, while normal foals becom e asymptomatic
carriers (McGuire, et at., 1990; Perryman, eta/., 1988).
Furthermore, there is no correlation between d ecreased viremia
and the level of neutralizing antibody, indicating that this is not
due to B cell function (Rwambo, et at., 1990a).

Together, these

provide in vivo evidence of a role for cell-mediated immunity in
the control of EIAV d isease during the afebrile carrier stage.
Further evidence for the importance of cellular immunity in
control com es from studies of antigen specific proliferation of
PBMC from EIAV infected horses.

The lymphoproliferative

resp o n se increases shortly after primary infection, d e c re a se s
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during the asymptomatic phase, but increases with recurrent
febrile episodes (Kono, et at., 1976a).
vitro

The cells involved in in

lymphoproliferation response are T lymphocytes.

Nylon

wool purified T lymphocytes, but not B cells or monocytes,
respond to EIAV antigen stimulation in vitro (Shively, et at.,
1982).

PBMC's from EIAV infected horses are able to kill virally

infected equine dermal cells in a direct cytotoxicity assay
suggesting a potential role for cytotoxic lymphocytes (Fujimiya,
et at., 1979). As with HIV, ADCC has been suggested to be
important in the initial immune response to EIAV.

ADCC was

dem onstrated against autologous EIAV infected lymphoblasts

in

vitro during the acute, but not the chronic stage of EIAV
(Q erencer, et at., 1989). Again, the in vivo importance of this
response is not known.

Indeed, ADCC probably contributes little to

the immune control during the carrier state since it is only
present at the initial stage of infection.
vitro

All of this in vivo and in

evidence supports that cellular immunity plays an important

role in controlling this lentivirus disease.

N evertheless, the

specific viral antigens recognized remain unknown.

Chapter II
Materials and Methods
Ponies
Grade ponies ranging from 2 to 7 years of age and weighing
100 to 300 kg were used in all studies.

Prior to entering the

study the ponies were tested for exposure to EIAV by AGID and
western blot analysis (Isset, et at., 1988).

They were housed in

screened box stalls within a screened facility, in order to protect
from hem atophagous insects, and fed a complete pelleted ration
(Purina Mills, St. Louis, Mo.).

The ponies received routine

immunizations which included a tetanus toxoid, inactivated
Western and Eastern encephalitis viruses, inactivated equine
influenza viruses A1 and A2, an avirulent spore vaccine for
anthrax, and a modified live-virus vaccine for equine
rhinopneumonitis.

They were routinely treated with Ivermectin

(Merck, Rahway, N.J.) for intestinal parasites.

At least 60 days

p assed between the final routine immunization and entry into this
study.

Throughout the study, rectal tem perature and clinical

status were monitored twice daily.

Serum, plasm a and whole

blood sam ples were routinely collected aseptically in vacutainer
tubes by jugular venipuncture.
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Virus Strains
EIAV virus strains used in this study were generously
provided by Sue Hagius (Department of Veterinary Science, LSU).
Prototype-ElAV (prototype), derived from the virulent Wyoming
strain of EIAV, w as attenuated by in vitro

propagation in primary

fetal equine kidney (FEK) cells (Issel, et a/., 1988).

The prototype

virus infects ponies, but seldom induces severe clinical disease.
A pathogenic variant of the prototype virus w as obtained from a
Prototype-infected pony and w as subsequently propagated in vitro
in the presence of neutralizing antibodies (Rwambo, et at., 1990b).
In spite of the repeated in vitro

p assag es of this isolate, which

had undergone two series of endpoint dilution "clonings” in
addition to its extensive cultivation in equine fibroblastic cells,
it retains its virulence in ponies and has becom e our reference
virulent challenge virus.

Its infectivity in ponies w as 107 -5

m edian horse-infective d o ses (HID5 0 ) per ml of cell culture fluid.
This challenge strain w as used because of its virulence, its
purity, and the lack of cross-neutralization between it and the
prototype cell-adapted strain.

Ponies surviving primary

infections with this strain for 100 days p o sse ss neutralizing
antibodies to the infecting strain but have no detectable
neutralizing antibody to the prototype strain.
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Cell Preparation
Peripheral blood sam ples were obtained from the jugular
vein and aseptically collected into heparinized (10 U/ml)
vacutainer tubes.

Buffy coat cells were obtained by

centrifugation (750 x g; 10 min) and resuspended in phosphate
buffered saline (PBS).

Peripheral blood mononuclear cells (PBMC)

w ere subsequently isolated by differential sedim entation through
Ficoll-Paque (Pharm acia LKB Biotechnology, Piscataway, NJ)
gradients (600 x g; 30 min).

The Pharmacia protocol recommends

400 x g ficoll spin with human sam ples, but upon comparison 600
x g gave better yields with equine sam ples.

The PBMC enriched

interface cells were w ashed three times with saline (150 x g; 10
min) and resuspended in medium (RPMI-1640 supplem ented with
20 mM HEPES buffer, antibiotics, glutamine, 2-m ercaptoethanol
and fetal calf sera (FCS, 5% v/v)).

Optimal culture conditions

were determined by comparing various concentrations and
additions or deletions of media supplements.

Cell num bers and

viability were determined and the cells resuspended at 1 x 10®
cells/ml in medium.

Cells were prepared fresh for each

experiment, since frozen buffy coats exhibited a loss in lytic and
serine e s te ra s e activity.

Lymphocyte Proliferation
Peripheral blood mononuclear cells (PBMC; 105) were
cultured in medium in triplicate wells of 96-well, roundbottomed microtiter plates (Costar, Cambridge, MA).

Each virus

16
and mitogen w as tested at four different concentrations per
assay.

Prototype and virulent virus were added to the wells at

1/20, 1/60, 1/200, and 1/600 dilutions of the virus stock.
Formalin-inactivated virus w as initially diluted 1/1000 with PBS
and then added at the sam e dilutions a s live viruses.

Pokeweed

mitogen (PWM; GIBCO/BRL, Gaithersburg, MD) was added at final
concentrations of 4, 2, 1 and 0.5pg/ml.

All of the above dilutions

were m ade in medium and diluted sam ples were added to the wells
in 100jil volumes of medium.

Unstimulated control wells

contained cells in media only.

The final volume of all cultures

w as 200pl.

The plates were incubated at 39°C in a humidified, 5%

CO2 incubator.
Lymphocyte proliferation was m easured by the incorporation
of 3 H-thymidine into cellular DNA.

The cells were pulsed with 0.5

pCi of 3 H-thymidine (New England Nuclear, Boston, MA) for 4 hours
on the sixth day of the culture period.

The best incubation time

for proliferation w as determ ined by comparing several time
points.

The plates were then stored frozen (-20°C) until the DNA

w as harvested onto glass fiber filter paper for liquid scintillation
counting.

The lymphoproliterative response is expressed either a s

counts per minute (CPM) or stimulation indices (SI), defined a s the
CPM of cells cultured with antigen or mitogen divided by the CPM
of cells cultured in medium alone.

The CPM of three replicate

cultures for the optimal dose of antigen or mitogen were used for
all determ inations.
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Nylon Wool T Cells
The nylon wool columns were prepared a s described by
Henry, et a/., 1980 in Selected Methods in Cellular Immunology.
The PBMC's were layered on the nylon wool column which retains
the macrophages, monocytes, and B cells.

The T cell enriched

population w as collected in media and washed.

The stimulators

were autologous PBMC's which were irradiated at 10? cells/ml
with 1000 rads by either X-ray (16 1/2 min, 250 Kv, 10 mA) or
cobalt (60Co; 30 sec).

Several radiation dosed were tested in

order to determ ine the optimal dose for stimulation without
proliferation.

After irradiation and washing, the autologous

PBMC's were incubated with the virus or antigens for at least 30
min. The nylon wool T (NWT) cells and the irradiated PBMC's were
then cultured at a 3:1 ratio (1 x 105 NWT/well ; 3 x 104 irradiated
PBMC/well).

Separation of Equine Lymphocytes
The murine monoclonal antibody EqT3 which recognizes a
cell-surface antigen on mature equine T lymphocytes was
purchased from VMRD Inc. (Pullman, WA). Approximately 5 x 10®
ElAV-stimulated (5 days) PBMC or NWT were resuspended in
phosphate-buffered saline (PBS) containing goat se ra (10% v/v)
and incubated on Ice for 30 min with the EqT3 monoclonal
antibody.

The labeled cells were w ashed with ice-cold PBS (3

mis; 200 x g; 10 min; 4°C) and incubated an additional 30 min with
a fluorescein isothiocyanate (FITC)-conjugated anti-m ouse
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immunoglobulin (Sigma).

In order to determine the optimal

working dilution, the EqT3 and the FITC were titered prior to use
at a fixed concentration.

The cells were again w ashed with PBS

and resuspended in RPMI-1640 containing goat sera (10% v/v).

The

labeled and unlabeled cells were sorted in a Becton Dickinson
model 440 flow cytometer. Sorted cells were collected into 15 ml
centrifuge tubes containing ice-cold medium.

Cell viability and

percent recovery were determined for each sorted population. The
cells w ere resuspended at 10® cells/ml in medium and pulsed
with ^H-thymidine a s described above.

Serine E sterase Assay
Serine e ste ra se activity in the lymphocyte cultures w as
m easured as previously described (Horohov, eta!., 1988) with
modifications.

Stimulated cells were w ashed in situ with PBS

and resuspended in 100^1 of 50 mM Tris buffer (pH 8.1) in 96-well
plates.

The cell pellets were lysed by freezing and thawing.

substrate, 400nM

The

N-alpha-benzylocarbonyl-l-lysine thiobenzyl

ester (Sigma Chemical Co., St Louis, MO) plus 400pM 5,5'-thio-bis2-nitrobenzoic acid (Sigma) in 100pl Tris buffer were added to
each well.

The plates were incubated 2 hrs at room tem perature

in the dark, and the OD450 was read in an optical plate reader
(Dynatech Laboratories, Chantilly, VA).

A standard curve from

which serine esterase units could be calculated w as generated for
each assay using serial dilutions of trypsin (Sigma).
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Lectin-M ediated

Cytotoxicity

The PBMC's were stimulated as described above and after 6
days the 5 1 Cr-labeled murine A20 targets (100pCi (Na2)51C r0 4
/1 0 6 cells; 2 hrs; 37°C) were added to the effectors (stimulated
PBMC). The lectin PH A w as added at 4pg/ml in order to bypass the
need for specific recognition.

T hese were incubated with effector

target ratio (E:T) of 90:1, 30:1, and 10:1 for 4 hours at 39°C. The
supernant was harvested (Skatron SCS, Nonway) and counted on a
gam m a counter to determine the amount of 5 1Cr released from the
labeled targets. The cytolytic response is expressed a s lytic units,
which are defined as the amount of activity in 107 effectors that
c a u ses lysis in 30% of the target cells.

Pony Vaccination
To prepare the inactivated whole-virus vaccine, a 2.0 mg/ml
solution of purified prototype EIAV w as treated with 0.8%
formaldehyde at 4°C for 24 hours, neutralized with 2% sodium
bisulfite, and then dialyzed overnight with 0.01 M phosphate
buffer. The EIAV envelope glycoprotein (gp 90 and gp 45)
preparation (provided by R.C. Montelaro, University of Pittsburgh)
w as produced by fractionation of the gradient-purified EIAV by
lentil lectin affinity chrom atography, a s detailed previously
(Montelaro, et a t, 1983).

The final preparations of formalin-

inactivated virus and lectin affinity-purified envelope
glycoproteins w ere then tested for residual infectious virus in
flask cultures of FEK cells.

All test for infectivity of the
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formalin-inactivated and the subunit preparations were negative.
For immunization, the preparations were mixed with equal
volumes of adjuvant (Syntex Laboratories, Palo Alto, CA) at final
concentrations of 6 mg of threonyl-muramyl dipeptide per dose of
vaccine.

The final concentrations of the vaccines were 1 mg of

formalin-inactivated prototype EIAV or 200pg of the lectin
affinity-purified

viral glycoprotein

fraction.

Ponies were vaccinated at 0, 2, and 6 w eeks with either
formalin-inactivated prototype (6 ponies) or subunit (8 ponies)
vaccines.

Control ponies received either a tissue culture sham (2

ponies) or adjuvant (2 ponies) only.
Challenges were with the prototype or virulent strain and were
given 12 w eeks after the first dose was administered.

Ponies

were monitored for viremic and febrile episodes following
infection (Issel, et al., 1992).

P ep tid es
The tymphoproliferation and serine esterase a ssa y s were
also done by stimulating in vitro
proteins.

with peptides and internal

The peptides (graciously provided by J. Ball, University

of Pittsburgh) w ere selected based on predicted T cell epitopes
(Ball, et a/., 1992), results of preliminary proliferation screens,
and their availability.

The envelope peptides were all purified

using reverse-phase high pressure liquid chromotography (Ball, et
a i, 1992). The gag proteins (provided by R.C. Montelaro) were
prepared by reverse-phase HPLC (Ball, et at., 1988). Stocks were

prepared a t a final concentration of 1 mM.

For each assay the

stocks were diluted to 8, 5, 2.5, and 1.25 uM in culture media
without FCS and 100pl w as added to triplicate wells in 96 well
microtiter plates.

The plates were wrapped in plastic wrap and

stored at -70°C until the day of the assay.

The PBMC's or NWT's

w ere resuspended in media with 10% FCS and 100pl added to
p la te s

containing

th e

viral

concentration of 5% (v/v).

a n tig e n s,

giving

a

final

FCS

For lymphoproliferation a ssa y s, the

p lates w ere pulsed overnight (18 hrs) rather than 4 hrs a s
described above.

Chapter

III

Cell-Mediated Immune R esponse of Ponies Infected With
EIAV
Introduction
Cytotoxic T lymphocytes (CTL) play an important role in the
control and elimination of many viral infections (Larsen, et at.,
1984; Mitchell, et at., 1985).

In order for a CTL to destroy a

virally infected cell, it must first recognize the viral protein
fragm ents bound to a major histocompatibility complex (MHC)
class I molecule on the cell surface (Monaco, 1992).

This CTL

recognition is mediated by a membrane bound T cell receptor (TCR)
com posed of a and p chains.

The interaction of the TCR with the

viral fragment-MHC molecule initiates a multi-step process
leading to the destruction of the virus infected cell.
Similarly, the induction of the CTL response also requires
multiple step s including the activation, proliferation and
differentiation of the CTL precursor (Horohov, et at., 1987).
Proliferation is conveniently m easured using a 3 H -thym idine
incorporation assay.

CTL precursor differentiation can be

determined by measuring the induction of serine esterase, a
trypsin-like enzym e found in the cytoplasmic granules of
cytotoxic cells (Pasternack, et at., 1986), and m easuring the
lectin-mediated cytotoxicity.

Here the T cell response to EIAV

w as m easured using antigen specific proliferation, serine
22
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e ste ra se activity, and lectin-mediated cytotoxicity.

T hese

results provide evidence of multiple CM I responses to EIAV in
experimentally infected ponies.

R esults
PBMC from infaoted pnnifls proliferate in r e s p o n s e to EIAV
s ti m u la tio n :

In order to dem onstrate ElAV-specific proliferation, PBMC
from experimentally infected and control ponies were stimulated
with various d o ses of whole virus (Fig 1).

This

lymphoproliferative response is representative of the resp o n ses
observed for numerous ElAV-infected ponies.

By contrast, the

PBMC from the EIAV negative control pony did not proliferate in
response to any dose of EIAV.

T cells from infected ponies proliferate in r e s p o n s e to EIAV
s ti m u la tio n :

To determ ine which lymphocytes were proliferating nylon
wool purified T cells (NWT) prepared from PBMC from infected and
immunized ponies were stimulated in vitro with EIAV. The NWT
from an immunized pony proliferated in a dose-dependent manner
following stimulation with EIAV whole virus (Fig 2).

This graph is

representative of results obtained from num erous infected and
immunized ponies.
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Figure 1: Lymp ho proliferative response of PBMC from infected and
control ponies. Peripheral blood w as collected from an EIAV
negative (open square) and experimentally infected pony (closed
squares). The PBMC were incubated with EIAV whole virus and on
day six the 3H-thymidine incorporation w as m easured and and
reported a s total CPM.
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Figure 2: Lympho pro Iiterative response of NWT from an
immunized pony. Peripheral blood was collected three months
post immunization and the NWT incubated with EIAV whole virus
at various dilutions. On day six. the ^H-thymidine incorporation
w as m easured and reported as stimulation indices.
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T cells a r e th e proliferating cells:

While the results obtained using NWT indicated that T cells
were responsible for the lymphoproliferative response, it
remained possible that a contaminating subpopulation of non T
cells w ere responsible. In order to confirm that T cells were
proliferating in response to virai stimulation, virus stim ulated
cells were sorted into T cell and non T cell populations prior to
pulsing.

FACS analysis of PBMC labeled with a monoclonal

antibody to a T cell antigen is illustrated in Fig 3.

Using this

reagent it was possible to identify a T cell and non T cell
population.

In order to confirm the identity of the T cell fraction,

PBMC from normal EIAV negative ponies were stimulated with the
T cell mitogen phytohemagglutinin (PHA).

The pooled fluorescent

labeled cells were sorted into a T cell and non T cell population
prior to pulsing with ^H-thymidine.

The T cell fraction had

increased proliferation after stimulation (Fig 4).

After

dem onstrating that T cell proliferation could be identified

by

sorting, cells from a normal and an infected pony (one year post
infection) w ere stimulated in vitro
with 3H-thymidine (Fig 5).

with EIAV, sorted and pulsed

The cells from the uninfected pony and

the non T cells all had thymidine incorporation counts under 1000
cpm.

Although not shown here, the resting or unstimulated ceils

also had counts under 1000 cpm.

In contrast, the T cells of the

infected pony w ere udergoing significant proliferation with
counts over 10,000 cpm.

These results were repeated using cells

from other infected and normal ponies.
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Figure 3: EIAV stimulated cultures may be separated into a T cell
and non T cell population. 1 X 10® ElAV-stimulated equine cells
were labeled with the EqT3 monoclonal antibody and analyzed on
the FACS 440.
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Figure 4:
Equine T
prepared
activated
against a
cell were
harvested

Thymidine incorporation by PHA stimulated T cells.
(hatched bar) and non-T cell (solid bar) populations were
from pooled PHA-stimulated cultures by fluorescent
cell sorting using a monoclonal antibody directed
common T cell antigen (EqT3). Equivalent numbers of
incubated with ^H-thymidine for four hours and then
for counting.
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Figure 5: T celts from an infected pony proliferate in response to
EIAV stimulation. PBMC from EIAV negative and an experimentally
infected pony were stimulated with EIAV whole virus. The T
(hatched bar) and the non-T (solid bar) cells were separated by
fluorescent activated cell sorting using EqT3 monoclonal antibody.
1 X 105 cells were incubated with 3H-thymidine then harvested
and counted. These results represent the average CPM of replicate
wells from EIAV infected and uninfected ponies.
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PBMC from infected po nies h a v e in c re a se d se rin e e s t e r a s e activity
in r e s p o n s e to EIAV stimulation:

In order to determine if the in vitro

stimulation with EIAV

antigens lead to the generation of cytotoxic activity, PBMC from
experimentally infected and control ponies w ere stim ulated with
EIAV whole virus at various d o ses and assay ed for serine esterase
activity (Fig 6).

The serine e ste ra se activity detected is typical

of the response observed with various ponies.

The PBMC of the

EIAV negative control pony (open square) had no antigen specific
increase in serine esterase activity.

However, PBMC from the

EIAV infected pony (closed square) exhibited an antigen specific
increase in serine e ste ra se activity after in vitro

stimulation

with EIAV.

C orrelation of s e rin e e s t e r a s e activity a n d cytolytic activity:

In order to dem onstrate that the increase in serine esterase
activity w as associated with the induction of cytotoxicity, PBMC
from infected ponies stimulated in vitro

with EIAV were

a s s e s s e d for cytolytic activity using the lectin m ediated
cytotoxicity assay. A good correlation (R -0.79) w as observed
between cytolytic and enzymatic activities (Fig 7).

Thus, with

increased cytolytic activity a similar increase in enzymatic
activity w as seen , indicating that the serine e ste ra se assay could
be used a s an index for cytolytic activity.
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Figure 6: Serine esterase activity of PBMC from an infected and
control pony. Peripheral blood w as collected from an EIAV
negative (open square) and an experimentally infected pony (closed
square). The PBMC were incubated with EIAV whole virus after six
days and serine esterase activity determined. Serine esterase
units were calculated from a standard curve using trypsin.
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Figure 7: Correlation of serine esterase and lytic units. EIAV
whole virus stimulated PBMC from 8 ponies two months post
experimental infection were a sse sse d for cytolytic and serine
e s te ra s e activity.
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Comparison of proliferation, serine esterase, and cvtolvtic
activities in ponies infected with EIAV:
When PBMC from ponies experimentally infected two months
early with EIAV were assay ed for proliferation, serine esterase,
and cytolytic induction, variations were observed (Fig 8).

While

som e ponies responded in all three assays, others had little to no
response. Overall the immune responses correlated with the
clinical picture.

The ponies with multiple febrile episodes (ponies

632, 830, 844) during the first two months of infection had more
response than the ponies (ponies 823, 842, 826, 82, 831} with few
or no febrile episodes (C.J. Issel, personal communication).
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Figure 8: Comparison of proliferation, serine esterase, and
cytolytic activities in ponies infected with EIAV. PBMC from
ponies experimentally infected for two months were assay ed for
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(hatched bar) activities after EIAV whole virus stimulation.
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D iscussion
Viruses may be eliminated by multiple immune m echanism s,
including neutralization by antibody, antibody dependent cellm ediated cytotoxicity, interferon production, or by cellular
immune response involving sensitized T cells.

During EIAV

infection, there is no correlation betw een the level of neutralizing
antibody and the control of viremia (Rwambo.ef a/., 1990).

This

indicates that in EIAV infection, as with other viral infections,
cell-mediated immunity may be involved in d isease control.
in vitro

One

m easure of T cell response expressed is antigen specific

lymphocyte proliferation (Corradin, et a/., 1977).

Lymphocytes

from immunized or infected anim als will proliferate in vitro in
response to specific antigens to which they were sensitized to in
vivo . This lymphocyte proliferation can be m easured by
determining the increase in DNA synthesis.

Previous research has

shown that there is an increase in lymphopro(iteration shortly
after primary infection with EIAV and with recurrent febrile
episodes (Kono, et a i, 1976).
Antigen specific lymphoproliferation of PBMC and NWT from
experimentally infected ponies w as used to dem onstrate EIAV
specific cell-mediated immunity.
stim ulated in vitro

PBMC from EIAV infected ponies

with the virus had an antigen specific

increase in 3 H-thymidine incorporation.

Using flow cytometric

sorting of the cells into T cell and non T cell populations, the
proliferative response was found to be mediated by T cells .
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To further characterize this T cell proliferative response,
serine esterase activity of stimulated cells w as m easured.

Serine

e ste ra se is localized in cytoplasmic granules of cytotoxic cells.
This enzyme has trypsin like properties and is secreted by
cytotoxic celts during attack on target cells.

The exact role of

serine esterase is unknown, but it may function in the recycling of
cytotoxic effector cells by detaching the effector cell from the
target.

The serine esterase activity can be m easured in vitro

using a color metric assay (Pasternack, et a/., 1966).

in vitro

stimulation of PBMC from EIAV infected ponies resulted in an
antigen specific increase in serine e ste ra se activity, indicating
that cytotoxic cells may be involved in the cell-mediated immune
response to this virus.
Additional evidence that cytotoxic cells are involved, was
provided using a lectin-mediated cytotoxicity a ssa y of stimulated
PBMC from infected ponies.

The lectin phytohemagglutinin (PHA)

is added in this assay to by-pass the need for specific MHC
recognition.

When the results from the lectin-mediated

cytotoxicity assay and the serine esterase assay were compared a
good correlation w as observed between cytolytic and enzymatic
activities.

Thus, with an increase in cytolytic activity

increase in serine esterase activity w as observed.

a similar

This

dem onstrates that cytolytic activity is asso ciated with the
induction of serine esterase.

Taken together th ese data indicate

that the response is cell-mediated and possibly involves cytotoxic
T lymphocytes.
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While the precise role of these in vitro m easured CMI
responses in limiting EIAV infection remains unclear, som e
inferences may be m ade from the specific responses of the 8
experimentally infected ponies.

Though the immune response of

the experimentally infected ponies exhibited considerable
variation, the ponies that had marked in vitro responses to
antigen stimulation also had more febrile episodes during the
first 60 days of infection than those ponies with diminished in
vitro

responses.

It is not known whether there w as more

response in vitro due to the febrile episodes or if the immune
response in vivo was responsible for the febrile episodes.

The

latter possibility is particularly intriguing considering the
already well-established immunopathologic com ponents of this
d isease (Issel, et a/., 1986) and the fact that m acrophages serve
as the major target of the virus (McGuire, et at., 1986).

Im mu na

med iated lysis of infected m acrophages and the subsequent
release of pyogenic cytokines is consistent with the observed
pathology.

Additional studies on the role of cell-mediated immune

responses in the pathogenesis of this disease are clearly needed.
In summary, these studies using PBMC and NWT's from EIAV
experimentally infected ponies dem onstrate a cell-m ediated
immune response.

Thus, in EIAV infection a s with other viral

infections, the CMI may be involved in the control of clinical
disease.

There is the possibility, however, that the CMI may also

contribute to the pathogenesis a s well.
implications for EIAV vaccine design.

This h as important

Chapter IV
Cell-Mediated Immune R esponaes to Equine Infectious
Anemia Vaccines
Introduction
The ability of the host's immune system to routinely control
lentivirus replication is unique to EIAV.

The immune m echanism

responsible for controlling EIAV replication rem ains unknown.

It

has been proposed that the cell-mediated immune responses may
be important since the decline in viremia does not correlate with
the appearance of neutralizing antibodies (Rwambo, et at., 1990a).
Immune responses mediated by T cells play an important role in
controlling various viral infections (Larsen, et at., 1984; Mitchell,
et at., 1985) but their role in lentivirus infections remains
undefined (Krowka, et at., 1990).

Cell-mediated immune responses

to HIV have been detected following both infection and vaccination
(Krowka, et at., 1990; Schrier, et at., 1989; Zarling, et at., 1986).
Likewise, lymphoproliferative and cytotoxic resp o n ses against
EIAV have been shown to follow EIAV infection, though the
significance of th ese responses in controlling virus replication
and d isease remains unclear (Gerencer, et at., 1989; Kono, et at.,
1976b; Shively, et at., 1982).
To investigate the role of cell-mediated immune responses
in protection from ElAV-induced disease, the T cell resp o n ses to
EIAV in vaccinated ponies were analyzed.
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The results dem onstrate
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that vaccination with either formalin-inactivated whole virus or a
glycoprotein subunit vaccine stimulated EIAV specific responses.
While there did not appear to be any difference in the in vitro T
cell responses induced by either vaccine, significant differences
were observed in the response to the in vivo virus challenge.

R esu lts
PBMC from EIAV-vaccinated ponies proliferate in response to
stimulation with EIAV antigens:
PBMC from control ponies (Fig 9, top) and ponies vaccinated
with either a formalin-inactivated preparation of the prototype
strain of EIAV (Fig 9, middle) or a glycoprotein subunit
preparation (Fig 9, bottom) were stimulated with EIAV and control
antigens at various times during the vaccination protocol.

None of

the control ponies PBMC responded to EIAV stimulation prior to
challenge.

Prior to vaccination (week 0), the PBMC from the

vaccine group also failed to proliferate in response to stimulation
with EIAV antigens.

However, by the second week post

vaccination the PBMC from the vaccinated ponies proliferated in
response to EIAV stimulation (p< .01, ANOVA). The
lymphoproliferative response peaked during the sixth week, four
w eeks after the the second vaccine dose

but the third vaccine

d o se did not significantly augm ent the lymphoproliferative
response.

Differences were not observed in the proliferative

responses of PBMC stimulated with either prototype or virulent
EIAV strains or with the formalin-inactivated vaccine.
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Figure 9: Lymphoproliferative responses of vaccinated and control
ponies. Peripheral venous blood w as collected at various times
from control (top panel), formalin-inactivated (middle panel), and
subunit (bottom panel) recipients and the PBMC were incubated
with either PWM (open square), whole prototype EIAV (open
circle), formal in-inactivated prototype EIAV (closed circle), or
virulent EIAV (open triangle). Control cultures contained cells
incubated with medium (see Figure 11). All cultures were assayed
for lymphoproliferation on the sixth day using 3H -thym idine
incorporation and stimulation indices were calculated.
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The lymphoproliferative response to EIAV is mediated bv T cells;
In order to determ ine the identity of the proliferating cells,
the EIAV stimulated cultures were labeled with a monoclonal
antibody and sorted into T and non T cell populations prior to
pulsing with ^H-thymidine.

The results presented in Figure 10

dem onstrate that the T cells from EIAV infected ponies and ponies
vaccinated with each vaccine were proliferating in response to
stimulation with EIAV.

Stimulation indices for each group of

ponies are given in Table 1 and dem onstrate the T cell nature of
the lymphoproliferative response.
PBMC from EIAV vaccinated ponies are activated in vivo, bv EIAV:
Prior to challenge with EIAV, pony PBMC incorporated only
low levels of ^H-thymidine into their DNA in the ab sen ce of
antigenic stimulation (Fig 11, days -7 through 83).

However, upon

in vivo challenge with EIAV, the PBMC from ponies vaccinated
with formalin-inactivated whole virus (Fig 11, middle) and the
subunit vaccine (Fig 11, bottom) incorporated significant levels (p
< .001; ANOVA) of ^H-thymidine when placed into cultures
containing medium alone on days 95 through 116. This
spontaneous proliferation presumably resulted from the in vivo
activation of vaccine primed lymphocytes by the EIAV challenge
since the control ponies' PBMC did not exhibit this response
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Figure 10: T celts proliferate in response to EIAV stimulation.
Equine T (hatched bar) and non-T cell (solid bar) populations were
prepared from ElAV-stimulated cultures by fluorescent activated
cell sorting using a monoclonal antibody directed against a
common T cell antigen (EqT3). Equivalent numbers of cells (1 X
10 5/well) were incubated with 3H-thymidine overnight and then
harvested for counting. These results represent the percentage of
the total CPM of the unfractioned cells.
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Table 1: Lymphoproliferative Response of Equine T Cells to EIAVa

Stimulation

Ponies

I - C e lls

Indices
Non T-Cells

EIAV negative

1.0

0.8

EIAV infected

23.5

2.1

Subuint Vaccinated

13.2

0.8

Form. Inactivated Vaccinated

31.2

3.5

a P B M C were incubated five days with EIAV and then labelled with

the monoclonal antibody EqT3 for fluorescent activated cell
sorting. 10$ sorted cells were transferred to 96-well plates and
pulsed with ^H-thymidine. Stimulation indices
(C PM experim entai/C PM controi) were calculated using unstimulated
cells a s the control.
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Figure 11: PBMC from vaccinated ponies spontaneously proliferate
following in vivo challenge with EIAV. Peripheral venous blood
w as collected from control (top panel), formalin inactivated
vaccine recipients (middle panel), and subunit vaccinates (bottom
panel), at various times and the isolated PBMC placed into
cultures containing only medium. After six days in culture the
cells were pulsed with ^H-thymidine, harvested and counted. The
results represent the average CPM for the ponies within a group.
Asterisks indicate days of vaccination and the arrow indicates the
day of challenge.
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(Fig 11, top).

Both prototype (Fig 11, open circles) and virulent

(Fig 11, closed circles) challenges stimulated this spontaneous
lymphoproliteration response in the vaccinates, though with som e
noteworthy differences.

Both viral challenges stimulated

spontaneous proliferation of the PBMC from the formalininactivated whole virus vaccinates (Fig 11, middle) with
som ewhat higher, though not significant (p > .2), levels of 3 Hthymidine incorporation were observed for the PBMC from virulent
challenged ponies.

Conversely, the spontaneous ^H-thymidine

incorporation by the PBMC from subunit vaccinates challenged
with virulent virus w as significantly less (p <.001) than that
following prototype challenge (Fig 11, bottom).

PBMC associated serine esterase activity varies between the
vaccine recipients following EIAV challenge:
The intracellular granules of cytotoxic T lymphocytes and
natural killer cells contain serine e ste ra se s referred to a s
granzym es (Jenne, et a i, 1988).

The activation of these cytolytic

effector cells results in an increase in serine e ste ra se activity
(Pasternack, et at., 1986; Welsh, et at., 1990).

In order to

determ ine if th ese effector cells were being activated in the
challenged ponies, we assayed freshly isolated PBMC for serine
esterase activity following challenge with EIAV (Fig 12).

PBMC

from the formalin-inactivated vaccine recipients (six ponies)
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Figure 12: PBMC-associated serine esterase activity from EIAV
challenged ponies. PBMC were assayed for serine esterase
activity one week following challenge with either prototype (open
bars) or virulent EIAV (hatched bars). Serine esterase units were
determined from a standard curve using trypsin. The results
represent the mean for PBMC from all the ponies within each
group.
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exhibited elevated levels of serine e ste ra se activity following
challenge with either strain of the virus.

Likewise, the PBMC

from the subunit vaccinated ponies (eight ponies) also exhibited
high levels of serine e sterase activity one week after challenge
with prototype virus.

However, the PBMC from the subunit

vaccinated ponies challenged with virulent virus exhibited low
levels of serine e ste ra se activity which were not different from
the control ponies.

Formalin-inactivated whole virus vaccine recipients w ere
pro tected :
Ponies were monitored daily for viremic and febrile
episodes following challenge with the prototype or virulent virus
strain.

Table 2 sum m arizes the clinical results of challenged

vaccinated ponies (Issel, et at., 1992).

Ponies (6 ponies) receiving

the formalin-inactivated whole virus vaccine w ere protected from
clinical disease.

The subunit vaccine recipients (8 ponies) were

protected from infection with prototype challenge, but not the
virulent challenge.

The control ponies w ere not protected.
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Table 2:

Clinical results of pony vaccination and challenge.

No Vaccines
Protod Virulent6
F ev erf

Subunit Vaccine^
P roto Virulent

FI Vaccine^
PlfltQ V irulent

C

ViremiaO +

a Control ponies received either a tissue culture sham or adjuvant
at 0, 2, and 6 weeks.
b Ponies were vaccinated at 0, 2, 6 weeks with 200pg of viral
glycoprotein in MDP adjuvant.
cPonies were vaccinated at 0, 2, 6, weeks with 1mg of formalininactivated prototype EIAV in MDP adjuvant.
d Prototype-EIAV, derived from the virulent Wyoming strain of
EIAV, w as attenuated by in vitro propagation in primary fetal
equine kidney (FEK) cells. Ponies were challenged with 10,000
infectious doses.
6Virulent-EIAV, a pathogenic variant of prototype virus that w as
obtained from a prototype infected pony and w as propagated in
vitro in the presence of neutralizing antibodies. Ponies were
challenged with 10,000 infectious doses.
fFever, rectal tem perature i 39°C
OViremia, determined by tissue culture and detection of viral
antigens
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D iscussion

Infection with various viruses leads to the in vivo
activation and expansion of T lymphocytes, which proliferate in
vitro

in response to stimulation with viral antigens (Larsen, et

al., 1984; Mitchell, et al., 1985). The in vitro
lymphoproliferation response is m ediated primarily by virus
specific CD4+ helper T celts which provide help for the generation
of other antiviral immune responses (Sherm an, et at., 1983). Two
groups reported that EIAV infection also leads to the development
of an EIAV specific lymphoproliferative response which is
mediated by T cells (Kono, et al., 1976b; Shively, et al., 1982).
Kono and coworkers (1976b) reported that lymphocyte
proliferative responses to EIAV antigen were detectable two
w eeks post primary infection and prior to the onset of clinical
disease.

The results presented here dem onstrate that vaccination

with either an inactivated whole virus or a glycoprotein-enriched
subunit vaccine stimulates T cells capable of mediating an EIAV
specific lymphoproliferative response.

Significant

lymphoproliferative responses to EIAV were detected two w eeks
after the first dose was given.

It had also been reported that T

cell enriched lymphocyte cultures proliferate in response to EIAV
stimulation (Shively, et al., 1982).

Using a monoclonal antibody

specific for equine T cells and a fluorescent activated cell sorter,
we w ere able to dem onstrate that the cells proliferating in the
EIAV stimulated cultures were T lymphocytes.

Similar results
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were obtained with PBMC from vaccinated and infected ponies.
Thus, no apparent differences were observed in the
lymphoproliferative response induced by either vaccine or
between vaccinated and infected ponies.
Lymphocyte biastogenesis and increased serine esterase
activity follow in vivo

challenge with infectious virus and this

response is associated with the induction of virus-specific
cytotoxic T cells {Biron, et al., 1986; Welsh, et at., 1990).
Likewise, the PBMC from both groups of EIAV vaccinates exhibited
spontaneous proliferation and elevated serine e ste ra se activity
following in vivo challenge with EIAV. The PBMC from control
ponies, however, failed to respond in a like manner.

These results

indicate that primary infection with EIAV may not be effective at
stimulating a cytotoxic T cell response.

The blastogenic and

serine este ra se response observed in the challenged vaccinates
may thus represent a memory cytotoxic cell response.
While no significant differences were detected between the
vaccinates regarding their in vitro
antigens, the in vivo
w as quite different.

response to the various EIAV

response to the two different viral strains

Even though the PBMC from both groups of

vaccinates exhibited similar levels of spontaneous proliferation
and serine e ste ra se activity following prototype challenge, the
subunit recipients' PBMC exhibited much lower levels of 3 h thymidine incorporation and no elevation of serine e ste ra se s after
virulent challenge.

Thus the subunit vaccine appears to have

stimulated a strain specific response in contrast to the c ro ss
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reactive response to the whole virus vaccine.

This restricted

response may represent a failure of the subunit vaccine to prime
cross-reactive T cells, particularly cytotoxic T cells, which
would respond to virulent virus antigens.

One explanation for this

failure is that the subunit lacked sufficient quantities of the
stimulatory antigen.

A likely candidate for the missing antigens

would by the core proteins which were much reduced in the
subunit preparation (R. Montelaro, personal communication).

Core

proteins have been shown to serve as targets for cell-mediated
immune responses in other lentivirus infections (Nixon, et a/.,
1988).

Alternatively, the processing of the virus to generate the

subunit vaccine could have destroyed important T cell epitopes on
viral proteins, including the envelope proteins.

Further studies

will determ ine which viral antigens stim ulate cell-m ediated
immune responses in infected and vaccinated ponies.
The significance of the disparity in the cell-mediated
immune responses stimulated by the two vaccines is not yet
known.

It w as recently reported that ponies receiving the whole

virus vaccine were protected from infection by homologous virus
(Issel, et a/., 1992).

Though th ese ponies could be infected with a

heterologous virus, they had reduced levels of virus replication
and no clinical disease.

Ponies receiving the subunit vaccine were

also protected from infection with homologous virus and also
becam e infected after challenge with the heterologous virus.
Unlike the whole virus recipients, th ese ponies exhibited signs of
more serious clinical d isease than the controls.

In neither ca se

w as protection from homologous challenge associated with the
presence of neutralizing antibodies.

It is tempting to speculate

that protection against d isease following homologous challenge
w as conferred by the induction of the cytotoxic cell response
associated with the increased serine e sterase activity.

D isease

exacerbation in the subunit recipients could have resulted from an
inappropriate immune response featuring a diminished cytotoxic
cell response.

Chapter V
Cell-Mediated Immune Responae to EIAV Proteins and
Peptides In EIAV Infected and Vaccinated Ponies
Introduction
Cell-mediated immunity plays an important role in antiviral
immune responses (Larsen, et al., 1984; Mitchell, et al., 1985).

In

1979, Zinkernagel and Doherty reported that CTL were specific for
both viral antigens and self major histocompatibility complex
(MHC) class I molecules.

Although this MHC-restricted recognition

has been known for som e time, until recently very little was
known about the nature of the viral antigens recognized by the
MHC and the CTL. Recent studies suggest that the CTL recognize
degraded fragments of the antigen bound to an MHC class I
molecule (Elliott, et al., 1990; Bodmer, et al., 1989; Townsend, e t
at., 1986).

The current model of antigen recognition by T cells

involves the T cell receptor (TCR) recognizing a protein fragment
bound to the MHC molecule (Weiss, 1989).

Due to this interaction

between TCR and antigen fragment on MHC, there is interest in
identifying those epitopes of the antigen that are recognized by T
cells in viral infections.

Knowing the epitopes required for

induction of cell-mediated immunity could lead to the
developm ent of synthetic peptide vaccines, that are specific for
the response generated a s opposed to whole virus vaccines.
The results presented in this chapter show that synthetic
peptides of EIAV envelope glycoprotein can stimulate sensitized
53
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cells in vitro.

The proliferative and serine e sterase activity of T

cells from infected and vaccinated ponies in response to EIAV
peptides is used a s an index of cell-mediated immunity.

R esu lts
PBMC's from infected and vaccinated ponies proliferate in
response to EIAV peptide pools:
Peptide pools diluted to various pM concentrations w ere
used to stimulate PBMC from experimentally infected and whole
virus formalin-inactivated vaccinated ponies (Fig 13).
protein pool consist of p9, pi 1, p15, p26.

The gag

The gp 45 pool includes

two peptides (R34 and 51) and the 3 gp 90 peptide poofs are
described in Figure 14.

PBMC from the EIAV negative control pony

did not respond to any of the viral peptide pools.

PBMC from

infected and vaccinated ponies did proliferate in response to in
vitro

stimulation with EIAV peptide pools. Although som e

differences were observed between infected and vaccinated ponies
and with the five peptide pools.

To determine more specifically

what this proliferative response is directed against, the
individual peptides were examined.
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Figure 13: PBMC from infected and vaccinated ponies proliferated
in response to stimulation with EIAV peptide pools. Peripheral
blood w as collected from control (solid bar), experimentally
infected (hatched bar), and formalin-inactivated vaccinated
(speckled bar) ponies. The PBMC were incubated with either gag
pool consisting of p9, pi 1. p15, p26, or one of the gp 90 pools
described in Figure 14, or gp 45 pool consisting of two peptides
(R34 and 51). After six days in culture the cells were pulsed with
3H-thymidine, harvested and counted. Stimulation indices
(CPMexperimentai/CPMcontroi) werG calculated using unstimulated
cells a s the control.
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Figure 14: EIAV gp90 envelope peptide pools. Pool one (hatched
bars) contains peptides 2, V3A, V3B, V4, 12, pool two (striped
bars) contains peptides 4, V4A, V4B, 5B, 9V, and pool three
(speckled bars) contains peptides V5B, V5C, 10V.
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NWT's from infected and vaccinated ponies proliferate in response
to EIAV peptide stimulation:
Nylon wool purified T cells (NWT) from prototype infected,
virulent infected, and formalin inactivated whole virus vaccinated
ponies were stimulated in vitro with
gag proteins (Table 3 & 4).

EIAV envelope

peptides and

NWT from the EIAV negative control

pony did not proliferate following virus or peptide stimulation
(data not shown).

In contrast, NWT from all of the vaccinated and

infected ponies responded to stimulation with whole virus.
However, the proliferative response to the individual proteins and
peptides w as variable.

Table 3 contains the lymphoproliferative

results for the envelope gp 90 peptides.

While the ponies

exhibited different recognition patterns, som e trends were noted.
All of the ponies responded to the peptide V5B and the four
prototype infected ponies responded to peptides 2 and 4
near the amino terminus.

located

Table 4 shows the proliferative

response to the gag proteins and the gp 45 peptides.

While NWT

from all of the prototype-infected ponies responded to the four
gag proteins, there w as only minimal stimulation for the other
ponies tested. There w as little to no response to the gp 45
peptides am ongst any of the ponies.
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Table 3: NWT from infected and vaccinated ponies proliferate in
response to stimulation with EIAV envelope gp90 peptides.
NWT and irradiated autologous PBMC were cultured at 3:1
ratio with various envelope peptides. On day six, the 3Hthymidine incorporation w as m easured and stimulation
indices calculated. The stimulation indices of four d o ses
were averaged and the following rating system used:
+++++ SI » 4 ; + + + + S li.4 ; + + + S li 3 ; + + S li,2 ; + S I > 1 ;
+/- SI - 1.
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Table 4: NWT from infected and vaccinated ponies proliferate in
response to stimulation with EIAV gag proteins and envelope
gp45 peptides. NWT and irradiated autologous PBMC were
cultured at 3:1 ratio with various envelope peptides. On day
six, the 3 H-thymidine incorporation w as m easured and
stimulation indices calculated. The stimulation indices of
four d o ses were averaged and the following rating system
used; +++++ SI » 4 ; ++++ SI 4; +++ SI z. 3; ++ SI i 2;
+ SI >1; +/- SI - 1.

Ponv#
EIAY

FI Vaccine
£2
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Prototype Challenge
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N W T s from infected a n d vaccinated ponies h a v e in c re ase d serine
e s t e r a s e activity in re s p o n s e to EIAV p ep tid e stimulation:

NWT from infected and vaccinated ponies were stimulated
with EIAV envelope peptides and gag proteins at various d o ses and
assayed for serine esterase activity (Fig 15, 16, 17).

NWT from

the EIAV negative control pony had no antigen specific increase in
serine esterase activity (data not shown).

In contrast, all of the

infected and vaccinated ponies responded to in vitro
with EIAV whole virus.

stimulation

However, the serine esterase response of

NWT from the infected and vaccinated ponies were variable.

The

prototype infected ponies had increased activity to the gag
proteins, som e activity to the envelope gp 45 peptides, and some
response to the gp 90 peptides near the amino terminus (Fig 15).
The formalin-inactivated vaccinated ponies had increased activity
to the envelope gp 90 peptides located between amino acids 92
and 299, the infected ponies had little response in this region (Fig
16).

The virulent challenged ponies had increased activity to the

envelope gp 90 peptides located near the amino terminus and to
the gag proteins (Fig 17).

63

v>
a>
T>
a.
o>
A

2
4
5B
OV
10V
V3A
V3B
V4
V4A
V4B .
V5C
V5B
12
P®
p11
pi 5
p26
P*p51
R32

□
■
■
■

Pony 13
Pony 11
Pony 05
Pony 01

•

Corrected SEU

Figure 15: NWT-associated serine esterase activity from EIAV
prototype infected ponies. Nylon wool purified T cells and
irradiated autologous PBMC were cultured at 3:1 ratio with EIAV
peptides. After 6 days, the cells were assayed for serine esterase
activity. Serine esterase units (S E U ) were determined from a
standard curve using trypsin. The corrected S E U (SEUexperlmentai S E U co n tro i) were calculated using unstimulated cells a s the
control.
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Figure 16: NWT-associated serine esterase activity from EIAV
formalin-inactivated vaccinated ponies. Nylon wool purified T
cells and irradiated autologous PBMC were cultured at 3:1 ratio
with EIAV peptides. After 6 days, the cells were assayed for
serine esterase activity. Serine esterase units (S E U ) were
determined from a standard curve using trypsin. The corrected
S E U (SEUexperimentai * S E U Control) were calculated using
unstimulated cells a s the control.
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Figure 17: NWT-associated serine este ra se activity from EIAV
virulent infected ponies. Nylon wool purified T cells and
irradiated autologous PBMC were cultured at 3:1 ratio with EIAV
peptides. After 6 days, the cells were assayed for serine esterase
activity. Serine esterase units (SEU) were determined from a
standard curve using trypsin. The corrected SEU (SEUexperimentai SEUcontrol) were calculated using unstimulated cells a s the
co ntrol.
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D iscussion

Immune responses mediated by T lymphocytes play
important roles in controlling viral infections, but the ability of
th ese CMI responses to control EIAV disease is not clear.
Lymphocytes from sensitized anim als will proliferate in response
to specific antigens.

In order to determine which antigen epitopes

are responsible for this specific response, synthetic viral
peptides may be used for antigen specific proliferation.

Synthetic

viral peptides have been shown to induce an antigen specific T cell
proliferation with cells from HIV infected subjects (Berzofsky, e t
at., 1991; Krowka, et at., 1990; Schrier, et at., 1989; Berzofsky, et
at., 1988).
EIAV specific cell-mediated immunity w as dem onstrated by
antigen specific proliferation of NWT from infected and
vaccinated ponies in response to viral proteins and peptides.

The

formalin inactivated vaccine recipients had little proliferative
response to the gag proteins compared to the infected ponies.
This may be b ecau se with the formalin-inactivated prototype
virus the internal gag proteins were not processed or presented on
the cell surface in the sam e manner a s infectious viral particles.
In contrast, the vaccinated ponies lymphocytes responded
vigorously to the external envelope proteins.

The envelope gp 90

peptide V5B is located in a region predicted to be exposed a s an
antigenic loop (Bail, et at., 1992).

The lymphoproliterative results

indicate that this peptide may be important in the CMI response,
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even though this region w as not utilized as a B cell epitope (Ball,
et at., 1992).

Although the gp 45 peptides R32 and 51 are part of

the monoclonal binding site (Chong, et at., 1991), little T cell
response was observed.

These differences indicate that the B and

T cell epitopes are not the sam e. When the B and T cell epitopes
were compared for the sam e pony no overlap was observed
(Montelaro, personal communication).
To further characterize this proliferative response to EIAV
peptides, the serine este ra se activity of stimulated NWT was
m easured.

NWT from infected and vaccinated ponies responded

with increased serine e ste ra se activity to in vitro
with a panel of EIAV peptides .

stimulation

Thus, indicating that cytotoxic T

cells may be involved in the CMI response to EIAV. The results
show that the prototype infected, virulent infected, and the
vaccinated ponies have different serine esterase responses to the
panel of peptides and proteins.

The prototype challenged ponies

dem onstrated an elevated serine esterase response to the gag
proteins but not the envelope peptides.

This may be because the

gag response is to the whole protein with multiple epitopes as
opposed to individual peptide response.
to identify the gag epitopes.

Further studies will need

Both the serine este ra se and the

proliferative response with vaccinated ponies dem onstrate that
the formalin inactivated vaccine failed to stimulate a CMI
response directed against the gag proteins.

As stated above these

internal proteins may not be presented with an inactivated whole
virus vaccine.

The virulent infection stimulated a greater serine
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esterase response than the whole virus vaccine, but less than the
prototype infection.

At this time it is not known if there are

differences in the core protein of the two virus strains .

The

prototype infected ponies had increased proliferation and serine
e ste ra se activity with the gag proteins.

While the virulent

infected and the vaccinated ponies had different response profiles
to proliferation and serine esterase.

This may indicate that the

proliferation and serine este ra se assa y s are detecting different
subsets of T lymphocytes that are responding to peptide
stimulation. The prototype infected ponies proliferative and
serine esterase responses to gag proteins may be to different
epitopes, again indicating the need to identify gag epitopes.

The

proliferative and serine e ste ra se results show that sensitized
ponies responded to in vitro

stimulation with EIAV gag proteins

and envelope peptides, therefore indicating that the response is
cell-mediated and may involve cytotoxic T lymphocytes.
In summary, th ese studies using a panel of synthetic viral
proteins and peptides to stimulate NWT from vaccinated and
challenged ponies dem onstrate a cell-mediated immune response.
Thus EIAV like other viral infections, T cells are able to recognize
and respond to antigen fragments and this response may be
important in d isease control.

Chapter VI
C o n clu sio n s
Equine infectious anemia has been recognized as a viral
d isease of horses since the early 1900 (Vallee and Carre, 1904).
While clinical m anifestations of this d isease are severe, including
cycles of fever, depression, edem a, weight loss, acute hemolytic
anaem ia, and decreased platelet count (Issel, et a/., 1984),

EIAV

is unique among lentiviruses in that the infected host routinely
brings plasm a viremia and clinical d isease under immunological
control (Montelaro, et at., 1984).

EIAV thus provides a useful

model for evaluating which host immune responses are
responsible for conferring immunological control of a persistent
lentivirus infection.

There is evidence that cell-mediated

immunity plays an important role in the control of this disease.
When treated with immunosuppressive drugs horses which were
asymptomatic carriers have episodes of viremia and clinical
disease, suggesting CMI involvement (Kono, et at., 1976a).
Likewise, foals with CIO fail to clear EIAV viremia, while normal
foals becom e inapparent carriers (McGuire, et at., 1990; Perryman,
et at., 1988).

Additional support for CMI involvement in viral

control is there is no correlation between d ecreased viremia and
the level of neutralizing antibodies (Rwambo, et at., 1990a).
Further evidence that cellular immunity is important for d isease
control com es from studies of antigen specific proliferation of
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lymphocytes from EIAV infected horses (Kono, et at., 1976b;
Shively, et at., 1982).
in vitro

Together these findings provide in vivo and

evidence of a role for cell-mediated immunity in the

control of EIAV replication during the afebrile carrier state.
The work presented here provides further evidence that CMI
is important in the d isease control in EIA.

Antigen specific

lymphoproliferation of PBMC and NWT from experimentally
infected ponies dem onstrated EIAV specific cell-m ediated
immunity.

Positive identification that the proliferating cells

were T cells w as provided by FACS sorting.

An indication of

cytolytic cell induction w as also obtained using a colormetric
assay for serine esterases.

The serine esterase activity

correlated with lectin-m ediated cytolytic activity, indicating
that cytotoxic cells were involved. These in vitro

responses

provide further support for a CMI role in disease control in
infected ponies, but it is not known how this correlates in vivo.
To investigate the role of ceil-mediated immune responses in
protection from EIAV induced disease, the T cell responses to
EIAV in vaccinated ponies were analyzed.

Differences in

lymphoproliferative responses were not observed betw een
vaccinated and infected ponies.

However, following challenge the

vaccinated ponies exhibited spontaneous proliferation and
elevated serine este ra se activity which w as not observed in
control ponies.

This spontaneous response may represent a

memory cytotoxic cell response induced by the vaccine.

The

formalin inactivated whole virus vaccine and the subunit vaccines
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showed no significant differences in their in vitro

response to

various EIAV antigens, though the in vivo response to the virulent
and prototype challenges w as different.

After virulent challenge

the subunit vaccine recipients' PBMC exhibited lower proliferation
and no increase of serine esterase activity, while the prototype
challenge both vaccines exhibited similar levels of response.

This

restricted response may represent a failure of the subunit vaccine
to prime cross-reactive cytotoxic T cells.

The subunit vaccine

had diminished amounts of EIAV core proteins which may be
important antigens for inducing a cross-reactive response.
However, T cells from a formalin-inactivated vaccine recipient
failed to respond to in vitro

stimulation with the gag proteins,

indicating that these proteins may not have been responsible for
the cross-reactive response.

The protection observed with the

formalin inactivated vaccine following challenge could be due to
internal proteins other than gag. Another alternative is that the
external proteins on the surface of a whole virus vaccine differ
from the purified glycoproteins in the subunit vaccine.

Since the

formalin inactivated ponies T cells showed proliferative response
to several of the envelope gp 90 peptides, this possibility merits
further investigation.
In conclusion the results presented here show that infected
and vaccinated ponies dem onstrate an EIAV specific celt-mediated
immunity.

T hese data dem onstrated that T cells were

proliferating, but the major question left to answ er is which
su b set of T cells.

The lymphoproliferative response to virus may
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be more than one group of T cells, the fact that the proliferation
and serine esterase response to peptides were different supports
this concept.

It is possible that even different subsets of T helper

cells are stimulated.

The results show that the B and T cell

epitopes are different, therefore there may be separate epitopes
for each subset of T cells.

Knowing which epitope induces the

immune response needed for protection, is important for designing
future EIAV vaccines.

As w as seen with the subunit vaccine,

induction of the inappropriate immune response may result in
exacerbation of disease.
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